Baughn et al., 2023 - Google Patents
Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathiesBaughn et al., 2023
View HTML- Document ID
- 8570406911377728081
- Author
- Baughn M
- Melamed Z
- López-Erauskin J
- Beccari M
- Ling K
- Zuberi A
- Presa M
- Gonzalo-Gil E
- Maimon R
- Vazquez-Sanchez S
- Chaturvedi S
- Bravo-Hernández M
- Taupin V
- Moore S
- Artates J
- Acks E
- Ndayambaje I
- Agra de Almeida Quadros A
- Jafar-Nejad P
- Rigo F
- Bennett C
- Lutz C
- Lagier-Tourenne C
- Cleveland D
- Publication year
- Publication venue
- Science
External Links
Snippet
Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre–messenger RNAs (pre …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baughn et al. | Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies | |
| Colasante et al. | dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice | |
| Morabito et al. | AAV-PHP. B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy | |
| Weskamp et al. | Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS | |
| Arbab et al. | Base editing rescue of spinal muscular atrophy in cells and in mice | |
| Puls et al. | Regeneration of functional neurons after spinal cord injury via in situ NeuroD1-mediated astrocyte-to-neuron conversion | |
| US11680263B2 (en) | Micro-RNAS and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| Tai et al. | Axo-axonic innervation of neocortical pyramidal neurons by GABAergic chandelier cells requires AnkyrinG-associated L1CAM | |
| Uchida et al. | Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43 | |
| Liu et al. | Tbr1 instructs laminar patterning of retinal ganglion cell dendrites | |
| Valluy et al. | A coding-independent function of an alternative Ube3a transcript during neuronal development | |
| Passini et al. | Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy | |
| Yungher et al. | Viral vector-based improvement of optic nerve regeneration: characterization of individual axons’ growth patterns and synaptogenesis in a visual target | |
| Ait Benichou et al. | Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1 | |
| Liu et al. | CDYL suppresses epileptogenesis in mice through repression of axonal Nav1. 6 sodium channel expression | |
| Xu et al. | Maternal diabetes induces senescence and neural tube defects sensitive to the senomorphic rapamycin | |
| Fujimaki et al. | The endothelial Dll4–muscular Notch2 axis regulates skeletal muscle mass | |
| Zhou et al. | Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease | |
| Hirunagi et al. | Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS | |
| Wang et al. | Developmental cytoplasmic-to-nuclear translocation of RNA-binding protein HuR is required for adult neurogenesis | |
| Cheng et al. | Triggering receptor expressed on myeloid cells-2 (TREM2) interacts with colony-stimulating factor 1 receptor (CSF1R) but is not necessary for CSF1/CSF1R-mediated microglial survival | |
| Almutiri et al. | Non-viral-mediated suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of spinal cord dorsal column axons | |
| Arango-Lievano et al. | Cell-type specific expression of p11 controls cocaine reward | |
| Ramírez-Jarquín et al. | Rhes protein transits from neuron to neuron and facilitates mutant huntingtin spreading in the brain | |
| KR20240135602A (en) | Compositions and systems for RNA-programmable cell editing and methods for making and using the same |